## Edgar Filing: MEDIMMUNE INC /DE - Form 4

MEDIMMUNE I	NC /DE									
Form 4	_									
February 20, 200								0145.4		
FORM 4		OMB APPROVAL								
Washington, D.C. 20549									3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								January 31, 2005 average urs per . 0.5	
obligations may continue. <i>See</i> Instruction 1(b).	Section 17(	a) of the I	Public U	Itility Hol	ding Con		nge Act of 1934, of 1935 or Sectio 940	on		
(Print or Type Respo	nses)									
1. Name and Addres HOCKMEYER	Symbol	er Name <b>an</b> MMUNE		Ū.	5. Relationship of Reporting Person(s) to Issuer					
(1+)	Middle)					(Check all applicable)				
(Last)	3. Date of Earliest Transaction (Month/Day/Year) 02/15/2007			X Director 10% Owner X Officer (give title Other (specify below) Chairman, Pres., MediVentures						
				If Amendment, Date Original iled(Month/Day/Year)			<ul><li>6. Individual or Joint/Group Filing(Check</li><li>Applicable Line)</li><li>_X_ Form filed by One Reporting Person</li></ul>			
GAITHERSBU	RG, MD 208	78					Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
	ansaction Date hth/Day/Year)	Execution any	Date, if	3. Transactic Code (Instr. 8)	4. Securiti mAcquired Disposed (Instr. 3, 4	(A) or of (D) and 5) (A)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D) Price	(Instr. 3 and 4)			
Reminder: Report on	n a separate line	for each cla	ass of sec	urities bene	ficially owr	ed directly	or indirectly.			
					inform requir	ation cont ed to resp ys a curre	spond to the colle tained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: MEDIMMUNE INC /DE - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	\$ 31.25	02/15/2007		A		150,000		<u>(1)</u>	02/15/2017	Common Stock	150,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
reporting of the round ( round as	Director	10% Owner	Officer	Other				
HOCKMEYER WAYNE T ONE MEDIMMUNE WAY GAITHERSBURG, MD 20878	Х		Chairman, Pres., MediVentures					
Signatures								
William C. Bertrand, Jr., Attorney-in-Fact		02/20/2007						
<u>**</u> Signature of Reporting Person		Date						

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercisable in equal quarterly installments over a four-year period following date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.